The Effects Of The Coverage Gap On Drug Spending: A Closer Look At Medicare Part D
Author(s) -
Yuting Zhang,
Julie M. Donohue,
Joseph P. Newhouse,
Judith R. Lave
Publication year - 2009
Publication title -
health affairs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.837
H-Index - 178
eISSN - 2694-233X
pISSN - 0278-2715
DOI - 10.1377/hlthaff.28.2.w317
Subject(s) - copayment , prescription drug , medicare part d , point (geometry) , percentage point , drug , medical prescription , demographic economics , medicine , business , actuarial science , economics , health insurance , health care , finance , mathematics , pharmacology , economic growth , geometry
We calculated prescription drug usage in two groups of Medicare beneficiaries: employer group with no coverage gap, and individual Part D group with no coverage or some generic drug coverage in the coverage gap. Among those with employer coverage, 40 percent reached the doughnut hole, compared with 25 percent of those without such coverage. Overall, 5 percent went through the doughnut hole to reach the catastrophic coverage level. Those lacking coverage in the doughnut hole reduced their drug use by 14 percent; those with generic coverage reduced their use by 3 percent. Coverage of generic drugs with a $0-$10 copayment in the doughnut hole could be financed by, at most, a six-to-nine-percentage-point increase in initial coinsurance.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom